What Peptides Are Used For: Applications in the Literature

What the literature means by "peptides"

In pharmacology, a peptide is a short chain of amino acids — longer than a single amino acid, shorter than a full protein. A 2022 review in Signal Transduction and Targeted Therapy described therapeutic peptides as a distinct modality occupying the space between small-molecule drugs and biologics, combining the target selectivity associated with proteins with a smaller, more synthetically tractable structure (PMID 35165272). A 2015 review in Drug Discovery Today similarly characterised peptide therapeutics as a class that had moved from niche hormone replacement into a broad development pipeline, while noting that stability and delivery remained the central obstacles (PMID 25450771).

That framing matters for the question of what peptides are "for". The literature does not treat peptides as a single product with a single purpose. It treats them as a chemical format — one that has been applied to many different biological targets, with very different levels of evidence behind each application.

What peptides are used for: application areas in published research

A 2023 review of peptide-based drug discovery reported that the field had expanded across multiple therapeutic areas, supported by advances in synthesis, screening and structural design (PMID 36481586). A 2025 review in Signal Transduction and Targeted Therapy covered peptide-based drug development across delivery platforms, therapeutics and vaccines, indicating how wide the application space has become (PMID 40038239).

Metabolic disease and body weight

The most prominent recent application in the peer-reviewed literature is the GLP-1 receptor agonist class. A 2025 review in Nature Reviews Drug Discovery discussed GLP-1-based therapies in diabetes, obesity and additional indications being explored beyond those two settings (PMID 40281304). These are prescription medicines evaluated in regulated clinical trials, which places them in a different evidence category from research chemicals discussed in non-clinical settings.

Immune-mediated inflammatory disease

Oral delivery has historically been the weak point of peptide drugs. A 2025 narrative review in Advances in Therapy examined orally administered peptide therapeutics as an emerging modality in immune-mediated inflammatory diseases, reflecting formulation work aimed at overcoming gastrointestinal degradation (PMID 40439953).

Pain and itch signalling

Questions about peptides and pain are often answered in the literature through receptor pharmacology rather than through general "recovery" claims. A 2021 approval summary described difelikefalin as a peripherally acting kappa-opioid receptor agonist peptide approved for moderate-to-severe pruritus in haemodialysis patients (PMID 34674115). Separately, a 2019 Handbook of Experimental Pharmacology chapter reviewed ligands targeting the nociceptin/orphanin FQ peptide (NOP) receptor, a peptide receptor system studied in relation to pain and related indications (PMID 31119463). In both cases the mechanism described is receptor binding and downstream signalling — not tissue regeneration.

How peptides work, as described in reviews

Reviews consistently describe the same core mechanism: a peptide's amino acid sequence folds into a shape that binds a specific receptor or protein surface, producing or blocking a signal. A 2022 review reported that this high target specificity is the principal advantage of the class, and that it tends to come with lower off-target activity than is typical for small molecules (PMID 35165272). A 2018 paper on the peptide chemistry toolbox described how naturally occurring peptides have been chemically modified to convert them into drug candidates with improved properties (PMID 29395804).

Structural chemistry is a large part of why some peptides progress and others do not. A 2024 review in Angewandte Chemie discussed cyclic peptides as a format for drug development, noting the role of cyclisation in shaping conformation and improving drug-like behaviour (PMID 37870189). A 2022 methods chapter described sulfonium-tethered peptide chemistry as one approach used to constrain peptide structure (PMID 35761049).

How peptide research relates to "healing"

The verified literature summarised here does not establish a general wound-healing or tissue-repair mechanism for peptides as a category. What it describes is receptor-level signalling and target engagement: a peptide binds something, and a pathway changes. A 2022 review framed therapeutic peptides in terms of defined molecular targets rather than broad restorative effects (PMID 35165272). Claims that a given peptide accelerates recovery would need to be evaluated against trials for that specific compound and that specific indication, not against the class as a whole.

How peptide research relates to pain

As above, the pain-related literature in this set is receptor-specific. Researchers reviewing NOP receptor pharmacology described a defined signalling system under investigation (PMID 31119463), and the difelikefalin approval review described a peptide agonist authorised for an itch indication rather than for pain generally (PMID 34674115). Extrapolating from one peptide to another is not supported by these papers.

Do peptides work? How effectiveness is assessed in the literature

"Do peptides work" is not a question the literature answers as one question, because the class contains approved medicines, late-stage candidates, early screening hits and compounds with no human data at all. The relevant distinction in published reviews is regulatory stage. A 2015 review reported that peptide therapeutics had moved into mainstream drug development while continuing to face pharmacokinetic constraints (PMID 25450771), and a 2023 review reported continued expansion of the peptide pipeline driven by discovery and design advances (PMID 36481586).

Practically, that means evidence quality varies enormously within the category. Approved peptide medicines have been through controlled clinical trials with regulatory review, as illustrated by the approval summary for difelikefalin (PMID 34674115) and by the clinical literature on GLP-1-based therapies (PMID 40281304). Many other peptides discussed online appear only in preclinical or screening-stage publications, and display technologies such as phage display are explicitly described as discovery tools rather than sources of clinical evidence (PMID 34673942).

"Best peptides": why reviews do not rank compounds

Published reviews do not produce ranked lists of peptides. They organise the field by target, indication and chemistry. The 2022 Signal Transduction and Targeted Therapy review structured its coverage around applications and future directions rather than comparative rankings (PMID 35165272), and the 2025 review in the same journal organised peptide development by delivery platform, therapeutic and vaccine categories (PMID 40038239). A peptide that performs well against one target says nothing about a structurally unrelated peptide aimed at another.

Limitations researchers report

• Metabolic instability. A 2015 review reported enzymatic degradation and short circulating half-life as defining challenges for peptide drugs (PMID 25450771).
• Oral bioavailability. A 2025 narrative review framed oral peptide therapeutics as an emerging modality precisely because oral delivery has been difficult to achieve (PMID 40439953).
• Delivery generally. A 2025 review devoted substantial coverage to delivery platforms as a distinct problem area in peptide drug development (PMID 40038239).
• Structural optimisation burden. Reviews of cyclic peptides (PMID 37870189) and peptide modification chemistry (PMID 29395804) described extensive engineering being required to turn a binding sequence into a viable candidate.

Adverse Events: What Studies Report

The verified papers summarised here are largely reviews of chemistry, discovery and development rather than safety-focused trial reports, so they do not provide a consolidated adverse-event profile for peptides as a class. The 2025 Nature Reviews Drug Discovery review of GLP-1-based therapies discussed the clinical use of that class across diabetes, obesity and further indications, where tolerability is assessed within regulated trial programmes (PMID 40281304), and the 2021 approval review for difelikefalin described a medicine that underwent regulatory safety evaluation before authorisation (PMID 34674115). A 2015 review reported that pharmacokinetic limitations, including rapid degradation, shape how peptide candidates are formulated and evaluated (PMID 25450771). Safety information for any individual peptide belongs to that compound's own trial record, and compounds without human trials have no such record.

Regulatory context referenced in the literature

Some peptides are approved prescription medicines with labelled indications, as documented in approval summaries (PMID 34674115). Others exist only as research-use-only materials or as investigational candidates described in discovery-stage publications (PMID 34673942). The distinction between an approved medicine, an investigational candidate and a research chemical is the single most useful filter when interpreting any statement about what a peptide is "used for".

Educational disclaimer

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition or treatment decision. Nothing here describes a protocol, and no compound mentioned is endorsed for personal use.

References

• GLP-1-based therapies for diabetes, obesity and beyond (Nature Reviews Drug Discovery, 2025)
• Cyclic Peptides for Drug Development (Angewandte Chemie International Edition, 2024)
• Peptide therapeutics: current status and future directions (Drug Discovery Today, 2015)
• Therapeutic peptides: current applications and future directions (Signal Transduction and Targeted Therapy, 2022)
• Sulfonium-Tethered Peptide (Methods in Molecular Biology, 2022)
• Peptide-based drug discovery: Current status and recent advances (Drug Discovery Today, 2023)
• Phage display and other peptide display technologies (FEMS Microbiology Reviews, 2022)
• Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines (Signal Transduction and Targeted Therapy, 2025)
• Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics (Bioorganic & Medicinal Chemistry, 2018)
• NOP-Targeted Nonpeptide Ligands (Handbook of Experimental Pharmacology, 2019)
• Difelikefalin: First Approval (Drugs, 2021)
• Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review (Advances in Therapy, 2025)